Education
About Us
Working with TipRanks
Follow Us
Eli Lilly & Co (LLY)
NYSE:LLY
LLY Stock Chart & Stats
Day’s Range― - ―
52-Week Range$623.78 - $972.53
Previous CloseN/A
Volume1.27M
Average Volume (3M)4.06M
Market Cap
$592.15B
Enterprise Value$737.86B
Total Cash (Recent Filing)$3.22B
Total Debt (Recent Filing)$38.52B
Price to Earnings (P/E)41.5
Beta0.64
Next Earnings
Oct 30, 2025EPS Estimate
6.26Next Dividend Ex-Date
Aug 15, 2025Dividend Yield0.88%
Share Statistics
EPS (TTM)6.31
Shares Outstanding946,456,800
10 Day Avg. Volume6,549,605
30 Day Avg. Volume4,056,738
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap1.25
Enterprise Value/Revenue15.06
Enterprise Value/Gross Profit18.43
Enterprise Value/Ebitda45.34
Forecast
1Y Price Target
$946.50Price Target Upside49.00% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering21
Bulls Say, Bears Say
Bulls Say
EarningsLilly reported a substantial beat on the topline and EPS, and importantly raised the full year guide.
Financial PerformanceEli Lilly delivered a strong set of 2Q25 results and raised 2025 revenue guidance to $60-$62bn, offsetting some concerns around the trial results.
Market PositionMounjaro is now the market leader in the T2D GLP-1 market.
Bears Say
Clinical TrialsThe results of the ATTAIN-1 trial for Eli Lilly's oral obesity pill orforglipron underwhelmed by coming at the lower-end of expectations, delivering 12.4% weight-loss at 72 weeks.
Market CompetitionThere will be a shift in investor perception around oral obesity market dynamics, with Novo’s oral semaglutide emerging as a more viable competitor.
Regulatory ChangesCVS formulary change negatively affected Zepbound Rx in July and will be a headwind to the rate of growth in Q3.
Eli Lilly & Co News
LLY FAQ
What was Eli Lilly & Co’s price range in the past 12 months?
Eli Lilly & Co lowest stock price was $623.78 and its highest was $972.53 in the past 12 months.
What is Eli Lilly & Co’s market cap?
Eli Lilly & Co’s market cap is $592.15B.
When is Eli Lilly & Co’s upcoming earnings report date?
Eli Lilly & Co’s upcoming earnings report date is Oct 30, 2025 which is in 79 days.
How were Eli Lilly & Co’s earnings last quarter?
Eli Lilly & Co released its earnings results on Aug 07, 2025. The company reported $6.31 earnings per share for the quarter, beating the consensus estimate of $5.599 by $0.711.
Is Eli Lilly & Co overvalued?
According to Wall Street analysts Eli Lilly & Co’s price is currently Undervalued.
Does Eli Lilly & Co pay dividends?
Eli Lilly & Co pays a Quarterly dividend of $1.5 which represents an annual dividend yield of 0.88%. See more information on Eli Lilly & Co dividends here
What is Eli Lilly & Co’s EPS estimate?
Eli Lilly & Co’s EPS estimate is 6.26.
How many shares outstanding does Eli Lilly & Co have?
Eli Lilly & Co has 946,456,800 shares outstanding.
What happened to Eli Lilly & Co’s price movement after its last earnings report?
Eli Lilly & Co reported an EPS of $6.31 in its last earnings report, beating expectations of $5.599. Following the earnings report the stock price went down -14.136%.
Which hedge fund is a major shareholder of Eli Lilly & Co?
Currently, no hedge funds are holding shares in LLY
Eli Lilly & Co Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$946.50 (49.00% Upside)
$946.50 (49.00% Upside)
Blogger Sentiment
Bullish
LLY Sentiment 85%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 1.9M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $225.3M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.3%
Last 30 Days ▲ 3.5%
Last 30 Days ▲ 3.5%
News Sentiment
Bearish
Bullish news 40%
Bearish news 60%
Bearish news 60%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-28.27%
12-Months-Change
Fundamentals
Return on Equity
86.70%
Trailing 12-Months
Asset Growth
40.41%
Trailing 12-Months
Company Description
Eli Lilly & Co
Eli Lilly and Company (LLY) is a global healthcare leader based in Indianapolis, Indiana, that focuses on the research, development, manufacturing, and marketing of pharmaceutical products. The company operates in several sectors, including diabetes care, oncology, immunology, neuroscience, and pain management. Eli Lilly's core products include insulin therapies, cancer treatments, and medications for various chronic and acute conditions, including depression and autoimmune disorders.
LLY Company Deck
LLY Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted strong revenue growth, successful clinical trials, and strategic acquisitions, which were offset by challenges in pricing, market access, and geographical headwinds. The company remains focused on addressing these challenges and maintaining its growth trajectory.View all LLY earnings summariesLLY Revenue Breakdown
67.44% U.S.
15.36% Europe
9.48% ROW
4.03% Japan
3.69% China
LLY Stock 12 Month Forecast
Average Price Target
$946.50
▲(49.00% Upside)
Technical Analysis
Ownership Overview
10.30% Insiders
23.46% Mutual Funds
11.07% Other Institutional Investors
37.57% Public Companies and Individual Investors